The POWER trial: A randomised, two-armed open label phase 3 clinical trial on personalised dose optimisation with adjuvant tamoxifen therapy after breast cancer to investigate the impact on discontinuation and efficacy compared to standard of care

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522240-40-00

Enrollment

1100

Registered

2025-09-02

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The primary endpoint is discontinuation of tamoxifen.

Detailed description

BESS plus (2007) scale and subscales and the POWER symptom questionnaire, Quality of life questionnaire, Concentration of circulating plasma metabolites, Invasive disease-free survival (iDSF), Distant relapse-free survival (DRFS), Breast cancer specific survival (BCSS), Overall survival (OS), Mammographic breast density, Cost effectiveness and use of health care resources, Genetic polymorphisms in germline DNA, Biomarkers used for therapeutic drug monitoring

Interventions

DRUGTamoxifen Viatris 20 mg tabletter.

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary endpoint is discontinuation of tamoxifen.	—

Secondary

Measure	Time frame
BESS plus (2007) scale and subscales and the POWER symptom questionnaire, Quality of life questionnaire, Concentration of circulating plasma metabolites, Invasive disease-free survival (iDSF), Distant relapse-free survival (DRFS), Breast cancer specific survival (BCSS), Overall survival (OS), Mammographic breast density, Cost effectiveness and use of health care resources, Genetic polymorphisms in germline DNA, Biomarkers used for therapeutic drug monitoring	—

Measure

Time frame

—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026